Integrating Digital Pathology and AI in Breast and Gynecologic Cancer
Overview
Recent advances in digital pathology combined with artificial intelligence (AI) and molecular profiling have transformed the diagnosis and management of breast and gynecologic cancers. Integration of morphological, immunophenotypic, and molecular data enables improved prediction of treatment response and survival, while spatial transcriptomics deepens understanding of tumor heterogeneity.
Background
Breast and gynecologic cancers are complex solid tumors characterized by unique genomic features and immune microenvironments. Traditional pathology has evolved from pattern recognition to incorporating molecular drivers and spatial tumor microenvironment analysis. Digital pathology, enhanced by AI and machine learning, now allows quantitative extraction of morphologic features linked to genomics and prognosis. Despite advances, challenges remain in standardization, reproducibility, and clinical workflow integration.
Data Highlights
The FDA approval of whole-slide imaging (WSI) systems in 2017 facilitated broader clinical adoption of digital pathology. AI models, including deep learning architectures like convolutional neural networks and vision transformers, analyze thousands of morphological features to predict molecular alterations and clinical outcomes. Foundation models pretrained on millions of histopathology images improve performance and generalizability across institutions and staining protocols.
Key Findings
Breast cancer classification now routinely integrates hormone receptor status, HER2 amplification, and multigene assays guiding prognosis and treatment.
Endometrial carcinoma classification incorporates mismatch repair status, POLE mutations, and p53 abnormalities for refined risk stratification.
High-grade serous ovarian carcinoma is primarily TP53-driven with links to homologous recombination deficiency and BRCA1/2 mutations.
Cervical carcinomas are increasingly characterized by HPV-related molecular pathways and immune checkpoint expression.
Digital pathology has evolved from archival use to quantitative analysis enabling AI-driven diagnostics and prediction of treatment response.
Foundation AI models pretrained on large histopathology datasets demonstrate superior diagnostic performance and adaptability with limited training data.
Clinical Implications
Integrating digital pathology with AI and molecular data enhances diagnostic accuracy and enables personalized treatment strategies in breast and gynecologic cancers. Adoption of multimodal approaches can improve risk stratification and prediction of therapeutic response, supporting multidisciplinary clinical decision-making. Overcoming challenges in standardization and workflow integration is essential for widespread clinical implementation.
Conclusion
The convergence of digital pathology, AI, and molecular profiling is reshaping breast and gynecologic cancer diagnostics and management. Continued development and clinical integration of multimodal approaches promise improved patient outcomes through more precise and comprehensive tumor characterization.
References
Campanella et al. -- Real-world deployment of AI in pathology
